Randomised comparison study: eradication therapy for Helicobacter pylori with or without ecabet sodium after endoscopic submucosal dissection (ESD) of early gastric cancer

Not Applicable

Recruiting

• Conditions: H.pylori positive early gastric cancer patient who underwent an ESD.

• Registration Number: JPRN-UMIN000007735
• Lead Sponsor: Department of Gastroenterology, Kitasato University School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-04-12
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 330

Inclusion Criteria

Not provided

Exclusion Criteria

1 Patients with past H.pylori eradication therapy. 2. Patients with suspected gastrointestinal stenosis and diagnosed gastrointestinal stenosis. 3. Patients with a history of upper gastrointestinal tract ablative operation or the vagotomy. 4. Patients with the active overlap cancer except the gastric cancer. 5. Patients with severe liver, renal, cardiac or hematopoietic dysfunction. 6. Patients with hypersensitivity to ecabet sodium. 7. Pregnant or lactating women or women who intended to become pregnant during the study period. 8. Patients with a history of allergy to omeprazole, amoxicilline, clarithromycin, or penicilline. 9. Patients receiving atazanavir sulfate, pimozide, ergotamine component preparation, tadalafil(adcirca). 10. Patients with mononucleosis. 11. Inadequate to entry judged by investigator.

Study & Design

• Study Type: Interventional
• Study Design: Not specified